Core Insights - The conference call discusses the positive 12-month overall survival update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] Group 1: Company Overview - Immuneering's leadership team includes Co-Founder and CEO Ben Zeskind, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Matushansky, Chief Accounting Officer and Treasurer Mallory Morales, and Chief Business Officer E.B Brakewood [2] Group 2: Trial Information - The call will include forward-looking statements regarding the Phase IIa trial of atebemetinib, including the timing of additional data and the company's development plans [3] - Actual results and timing of events may differ materially from anticipated outcomes due to various risks and uncertainties [4]

Core Points - The conference call is focused on the positive 9-month update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] - Key executives from Immuneering, including the CEO and Chief Scientific Officer, are present on the call to discuss the trial results and future plans [2] Company Updates - Immuneering is currently conducting a Phase IIa trial for atebemetinib, which is aimed at treating first-line pancreatic cancer patients [1][3] - The management team is expected to provide forward-looking statements regarding the trial and the timing of additional data [3][4]